Chris Riley is a Senior Manager on the Strategic Insights team at H1. Chris works daily with H1 clients, both large and small, leveraging H1’s vast data lake to execute impactful strategic projects, from KOL engagement strategies, to patient cohort analysis, to clinical trial patient diversity plans and beyond. Chris is committed to ensuring that his clients get the most out of H1’s platform and data.
Prior to joining H1, Chris had a rich stint in life science consulting where his focus spanned across Commercial, Medical, and Research & Development projects. His fervor for life sciences finds its roots in academia where he spent over a decade immersed in research at Harvard, Dana Farber Cancer Institute, and the University of Texas. He enjoys leveraging his background to help clients enhance their own analytical capabilities to accelerate the development and launch of novel treatments for patients in need.
As key opinion leaders (KOLs), nurses can provide insights on unmet clinical needs, identify gaps in treatment options, and contribute to the development of better and more patient-centric solutions. Here are three core reasons why pharmaceutical companies should tap the power of nurses.